Skip to content

Cipla may extend losses on USFDA warning, HSBC cuts target price

According to analysts at HSBC, the USFDA#39;s warning letter to Cipla hints at a lengthy resolution timeline and incremental costs

Read More

​ According to analysts at HSBC, the USFDA#39;s warning letter to Cipla hints at a lengthy resolution timeline and incremental costs According to analysts at HSBC, the USFDA#39;s warning letter to Cipla hints at a lengthy resolution timeline and incremental costs  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish